Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist;Neuropatia motora com múltiplos bloqueios de condução associada a antagonista de TNF-alfa

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 3, 2010, Pages 452-454

  Carrilho, Paulo Eduardo Mestrinelli ^a   Araújo, Allan César Faria ^a   Alves, Orival ^a   Kotze, Paulo Gustavo ^b  

^a UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CASE REPORT; CROHN DISEASE; DEMYELINATING NEUROPATHY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LETTER; MOTOR NEUROPATHY; PATHOGENESIS; POSTERIOR TIBIAL NERVE PALSY; RADIAL NERVE PALSY; ULNAR NERVE PARALYSIS;

EID: 77954588458     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000300022     Document Type: Letter

References (13)

1. Feagan BG, Enns R, Fedorak RN, et al. Infliximab for the treatment of Crohn's disease:efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 2001; 8:188-198.
2. Hamilton K, Clair EW. Tumor necrosis factor alpha blockade: a new era for the effective management of rheumatoid arthritis. Expert Opin Pharmacother 2000;1:1041-1052.
3. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology 2005;44:132-133.
4. Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37:281-292.
5. Singer OC, Otto B, Steinmetz H, Ziemann U. Acute neuropathy with multiple conduction blocks after TNF-alpha monoclonal antibody therapy. Neurology 2004;63:1754.
6. Shin I-S J, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller-Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006;54:1429-1434.
7. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-1470.
8. Richette P, Dieudé P, Damiano J, et al. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004;31:2079-2081.
9. Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol 2006;33:1018-1020.
10. Liu J, Marino MW, Wong G. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
11. Miller FW, Hess EV, Claw DJ, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-249.
12. Latov N, Sherman WH. Improvement with etanercept (Enbrel) in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2000;48:473
13. Rodinò S, Saccà N, D'Amico T, Fragomeni A, Giglio A. Severe polyneuropathy complicating active Crohn's disease: rapid response to infliximab. GUT 2003; 52:1070.